Form 8-K - Current report:
SEC Accession No. 0000950170-25-047207
Filing Date
2025-03-31
Accepted
2025-03-31 07:32:29
Documents
3
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K maze-8k-q424_earnings.htm 8-K 36555
2 EX-99.1 maze-ex99_1.htm EX-99.1 181143
3 GRAPHIC img92905542_0.jpg GRAPHIC 14850
  Complete submission text file 0000950170-25-047207.txt   239486
Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Filer) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42490 | Film No.: 25788922
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)